Sector News

Categories

Borderless Insights

Image
Ditch Your CV Biases: Finding Your Next Leader Demands a Storyteller’s Curiosity
Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?

GSK to pocket $890 mln by halving stake in S.African drugmaker

March 14, 2015
Life sciences
(Reuters) – GlaxoSmithKline has decided to take profits in Aspen Pharmacare by halving its stake in the South African drugmaker, following a long investment in the firm.
 
The sale will be conducted through a share placing at a discount to the market price, which is expected to raise around $890 million.
 
Britain’s biggest drugmaker said on Thursday it would remain a 6.2 percent shareholder in Aspen and it had undertaken not to sell any more shares in the South African group for 180 days.
 
A source familiar with the matter said a price range of 365 to 385 rand per share had been set for the placement, representing a discount of 5.3 to 10.2 percent to Aspen’s closing price on Thursday.
 
The share sale is being run by Citi and UBS.
 
Simon Dingemans, GSK’s chief financial officer, said the disposal would help give his company flexibility to invest in new opportunities in the wake of a $20 billion-plus asset swap transaction with Novartis.
 
“As we continue to reshape the group around our core franchises and drive the benefits from the Novartis transaction, optimising our financial flexibility to invest behind these priorities is key,” he said in a statement.
 
“As a result we have decided now is the right time to realise further value from this successful relationship. We continue to believe in the strategy of Aspen and we remain committed to working together in the future.”
 
GSK said that the net profit on the disposal would not be included in core operating profit and core earnings in 2015, and GSK would no longer account for Aspen as an associate. (Reporting by Freya Berry, Vikram Subhedar and Ben Hirschler; Editing by Pamela Barbaglia, Greg Mahlich)

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

Read more
December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

Read more
December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

Read more
More news

How can we help you?

We're easy to reach